smecta® is an oral formulation of pharmaceutical clay indicated in the treatment of acute diarrhea in both adults and children, and the symptomatic treatment of digestive pain and chronic diarrhea in adults. The active substance in smecta® is diosmectite, a natural clay processed and purified for therapeutic use.
As of 31 December 2017, smecta® and other products in its range (flavors, OTC) are in about 60 countries. In 2017, smecta® sales represented 6.0% of total Ipsen sales, of which 75% were generated in China, France, and Russia, the product’s main markets. smecta® is Ipsen’s leading Consumer HealthCare product in terms of sales.
As of 31 December 2017, forlax® was granted marketing authorizations in about 50 countries. In 2017, 49% of forlax® sales were generated in France.
Etiasa® (mesalazine) is indicated in Inflammatory Bowel Diseases (Ulcerative colitis and Crohn’s Disease), for the treatment of mildl to moderate conditions and maintenance of remission.
Un laxatif, commercialisé en République Tchèque.
The Group granted exclusive licensing rights to the Menarini Group for Adenuric® in 41 countries. In addition, Ipsen continues to promote the product in France together with Menarini.
An analgesic for the treatment of moderate to severe pain.
Used for irritative cough, allergic cough, non productive cough with heart disease, tracheitis, bronchitis and other conditions.
smebiocta® (LP299V®), the first probiotic launched by Ipsen to maintain intestinal comfort.
In April 2016, Ipsen signed a license and supply agreement with Probi for the commercialization of its probiotic strain Lactobacillus Plantarum 299v (LP299V®). The agreement covers 18 markets, many with high growth potential, with an option to include additional countries.
In 2017, the product was launched in France, Czech Republic, Romania, and the Baltics.